The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The impact of post-transplant maintenance strategies on the QoL of patients with multiple myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, explains the post-transplant maintenance strategies for myeloma patients in terms of quality of life (QoL). Not all patients tolerate the standard of care lenalidomide, so clinical studies must consider a multi-agent maintenance approach without neglecting QoL, especially if this treatment will not significantly prolong overall survival (OS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
